TIDMABZA
RNS Number : 6355D
Abzena PLC
10 October 2018
Abzena plc
Exercise of options
Cambridge, UK, 10 October 2018 - Abzena plc (AIM: ABZA,
'Abzena', the 'Company' or the 'Group') announces that, on 10
October 2018, 672,980 new ordinary shares of GBP0.002 each in the
Company ('Ordinary Shares') were issued and allotted following the
exercise of share options by employees and former employees. The
new Ordinary Shares rank pari passu with the Company's existing
issued Ordinary Shares and have been admitted to trading on AIM
under the Company's block admission.
Total voting rights
Following the issue of the 672,980 new Ordinary Shares as set
out above, the Company's issued share capital comprises 214,893,379
Ordinary Shares with voting rights. No Ordinary Shares are held in
treasury. The total number of voting rights in the Company is
therefore 214,893,379. This figure of 214,893,379 Ordinary Shares
may be used by shareholders in the Company as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
Director New Ordinary Direct and indirect % of issued share
Shares resulting interest in Ordinary capital(1)
from option exercises Shares(1)
John Burt 151,673 2,302,238 1.1%
----------------------- ---------------------- ------------------
Julian Smith 83,253 608,672 0.3%
----------------------- ---------------------- ------------------
(1) As enlarged by the issue of 672,980 new Ordinary Shares
pursuant to the option exercise.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities/person closely associate
1(a) Name John Burt
1(b) Position / Status Chief Executive Officer
------------------ ------------------------
2 Reason for the Notification
2(a) Reason Exercise of Stock Options
2(b) Initial notification Initial
/ amendment
--------------------- --------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
3(a) Name Abzena plc
3(b) Legal Entity Identifier 213800SB5JV4O28JRM14
("LEI")
------------------------ ---------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
4(a) Description of the Abzena plc ordinary shares of
financial instrument, GBP0.002 each
type of instrument
Identification code GB00BN65QN46
-------------------------- -------------------------------------
4(b) Nature of transaction Exercise of 151,673 stock options
-------------------------- -------------------------------------
4(c) Price(s) and volumes(s) Price Volume
GBP0.0002 151,673
(exercise price)
----------------------------------------------------------- ----------
4(d) Aggregated information Price Volume
GBP0.0002 151,673
(exercise price)
----------------------------------------------------------- ----------
4(e) Date of transaction 10 October 2018
-------------------------- -------------------------------------
4(f) Place of the transaction N/a
-------------------------- -------------------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities/person closely associate
1(a) Name Julian Smith
1(b) Position / Status Director
------------------ -------------
2 Reason for the Notification
2(a) Reason Exercise of Stock Options
2(b) Initial notification Initial
/ amendment
--------------------- --------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
3(a) Name Abzena plc
3(b) Legal Entity Identifier 213800SB5JV4O28JRM14
("LEI")
------------------------ ---------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
4(a) Description of the Abzena plc ordinary shares of
financial instrument, GBP0.002 each
type of instrument
Identification code GB00BN65QN46
-------------------------- ------------------------------------
4(b) Nature of transaction Exercise of 83,253 stock options
-------------------------- ------------------------------------
4(c) Price(s) and volumes(s) Price Volume
GBP0.0002 83,253
(exercise price)
----------------------------------------------------------- ---------
4(d) Aggregated information Price Volume
GBP0.0002 83,253
(exercise price)
----------------------------------------------------------- ---------
4(e) Date of transaction 10 October 2018
-------------------------- ------------------------------------
4(f) Place of the transaction N/a
-------------------------- ------------------------------------
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive Officer +44 1223 903498
N+1 Singer (Nomad & Broker)
Aubrey Powell / Ben Farrow +44 20 7496 3000
Instinctif Partners +44 20 7457 2020
Melanie Toyne Sewell / Rozi Morris / Alex Shaw abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on ABZENA Inside products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Biology research studies, including immunogenicity assessment
of candidate biopharmaceutical products and bioassay
development;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development;
-- GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and
-- GMP analytical services for biopharmaceutical manufacturing projects.
For more information, please see www.abzena.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEADEEFDXPFFF
(END) Dow Jones Newswires
October 10, 2018 09:40 ET (13:40 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Jan 2025 to Feb 2025
Abzena (LSE:ABZA)
Historical Stock Chart
From Feb 2024 to Feb 2025
